EMA Authorised: Perjeta (pertuzumab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Perjeta (pertuzumab) for breast cancer in the European Union, with the decision dated 04/09/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Perjeta (pertuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 04/09/2025